Given the healthy outlook statement I'm surprised at the...

First 5 Last

Share
Profile

Follow
ormond

4,225 Posts.

26

01/02/17

18:34

Post #: 22297730
Share

Originally posted by Beany72 ↑

Good read, it was further confirmed again in an announcement by the company in October which is the last update we have had:

Outlook for the 2017 financial year Commenting on RXP’s outlook for FY17 and beyond, Mr Fielding said: “We have made a strong start to the 2017 financial year, and are expecting to deliver at the top end of our revenue growth guidance of 10-15%, and maintain a target EBITDA margin of 13-14%. “With an enhanced capability set and the One-RXP strategy deeply entrenched in our culture, we expect to see continued cross-practice growth in client work. We are seeing a growing level of spend in our sector as clients look to leverage design thinking and new technologies to help them grow their businesses which is helping to drive a strong pipeline of work across our specialist practices. “With a strong balance sheet in place and growing cashflow conversion, we continue to be very well placed to participate in industry consolidation. “Given the healthy outlook and strong financial position, our progressive dividend policy remains in place. We look forward to continuing to deliver excellent outcomes for our people, clients, partners, and our shareholders.”

There is also a more recently article published by them highlighting RXP as an attractive buy.
http://www.fool.com.au/2017/01/25/10-explosive-growth-shares-at-the-top-of-my-shopping-list/

Expand

Given the healthy outlook statement I'm surprised at the pressure on the RXP SP of late. A couple of average market updates by some other I/T co's has no doubt had some impact but looks a great buy at current SP in the lead up to the HY result.

RXP Price at posting: 87.0¢ Sentiment: Buy Disclosure: Held
4 Upvote

0 Great analysis

Reply

Top Stories

MTM

Australian Rare Earths bullish on early-stage uranium potential at Overland, SA

Chaos reigns markets – so let's take stock of where we're at ahead of December

PME

Pro Medicus signs landmark $330M deal to roll out imaging platform in US hospitals

SHN

Chimeric clocks $4.17M R&D tax rebate from Canberra

OCN

Southern Cross Gold zooms in on 9 new high-grade zones above 20g/t at Golden Dyke

ACW

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

MIN

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

Watchdog takes Webjet to court over alleged 'false' flight prices with hidden fees

WC8

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

There are more pages in this discussion • 14 more messages in this thread...

First 5 Last

Add RXP (ASX) to my watchlist

Given the healthy outlook statement I'm surprised at the...

Top Stories

Australian Rare Earths bullish on early-stage uranium potential at Overland, SA

Chaos reigns markets – so let's take stock of where we're at ahead of December

Pro Medicus signs landmark $330M deal to roll out imaging platform in US hospitals

Chimeric clocks $4.17M R&D tax rebate from Canberra

Southern Cross Gold zooms in on 9 new high-grade zones above 20g/t at Golden Dyke

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

Watchdog takes Webjet to court over alleged 'false' flight prices with hidden fees

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects